NorLevo is an oral emergency contraceptive, which is taken within 72 hours after unprotected sexual intercourse or contraceptive failure to prevent unwanted pregnancy.
Sosei has taken over the exclusive distribution rights to the product in Japan and Australia from Laboratoire HRA Pharma in April 2001.
ASKA Pharmaceutical has the commercialization rights for NorLevo in Japan, under an agreement signed between Sosei and ASKA Pharmaceutical.
Further, the company is planning to launch the product in the middle of May 2011.